Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism

Mojca Božič, Mojca Stegnar, Isabella Fermo, Anka Ritonja, Polona Peternel, Janez Stare, Armando D'Angelo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Mild hyperhomocysteinemia is recognized as a risk factor for venous thromboembolism (VTE), though its role in the thrombogenic processes is not understood. Its possible association with impaired fibrinolysis was investigated in 157 patients (61 women, 96 men) below the age of 60 years (43±11, mean±SD) with a history of objectively confirmed VTE. Patients had significantly higher fasting total plasma homocysteine (tHcy) levels than 138 apparently healthy subjects (8.0, 6.6-9.9 μmol/L vs. 7.2, 5.9-8.6 μmol/L, P=0.001; median, range between first and third quartile). In 17 of 157 patients (12%) hyperhomocysteinemia (tHcy>11.4 μmol/L for women and tHcy>12.6 μmol/L for men) was established. The adjusted odds ratio as an estimate of relative risk for VTE was 2.3 (0.8-7.0; 95% confidence interval). When patients with hyperhomocysteinemia were compared to patients without hyperhomocysteinemia, no significant differences in t-PA (antigen 9.2±5.5 μg/L and 9.7±4.7 μg/L, respectively; activity 1.3±0.5 IU/mL and 1.3±0.7 IU/mL, respectively) and PAI-1 (antigen 19.3±17.5 μg/L and 22.6±20.4 μg/L, respectively; activity 15.0±12.6 and 15.8±13.3 IU/mL, respectively) were observed. In conclusion, this study showed an association between mild hyperhomocysteinemia and VTE, but provided no evidence for an independent association between hyperhomocysteinemia and alterations in fibrinolytic proteins. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalThrombosis Research
Volume100
Issue number4
DOIs
Publication statusPublished - Nov 15 2000

Fingerprint

Hyperhomocysteinemia
Venous Thromboembolism
Homocysteine
Antigens
Plasminogen Activator Inhibitor 1
Fibrinolysis
Fasting
Healthy Volunteers
Odds Ratio
Confidence Intervals
Proteins

Keywords

  • Fibrinolysis
  • Homocysteine
  • Hyperhomocysteinemia
  • Vascular disease
  • Venous thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. / Božič, Mojca; Stegnar, Mojca; Fermo, Isabella; Ritonja, Anka; Peternel, Polona; Stare, Janez; D'Angelo, Armando.

In: Thrombosis Research, Vol. 100, No. 4, 15.11.2000, p. 271-278.

Research output: Contribution to journalArticle

Božič, Mojca ; Stegnar, Mojca ; Fermo, Isabella ; Ritonja, Anka ; Peternel, Polona ; Stare, Janez ; D'Angelo, Armando. / Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. In: Thrombosis Research. 2000 ; Vol. 100, No. 4. pp. 271-278.
@article{5069898a9f914e8e96ac4c64e763b073,
title = "Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism",
abstract = "Mild hyperhomocysteinemia is recognized as a risk factor for venous thromboembolism (VTE), though its role in the thrombogenic processes is not understood. Its possible association with impaired fibrinolysis was investigated in 157 patients (61 women, 96 men) below the age of 60 years (43±11, mean±SD) with a history of objectively confirmed VTE. Patients had significantly higher fasting total plasma homocysteine (tHcy) levels than 138 apparently healthy subjects (8.0, 6.6-9.9 μmol/L vs. 7.2, 5.9-8.6 μmol/L, P=0.001; median, range between first and third quartile). In 17 of 157 patients (12{\%}) hyperhomocysteinemia (tHcy>11.4 μmol/L for women and tHcy>12.6 μmol/L for men) was established. The adjusted odds ratio as an estimate of relative risk for VTE was 2.3 (0.8-7.0; 95{\%} confidence interval). When patients with hyperhomocysteinemia were compared to patients without hyperhomocysteinemia, no significant differences in t-PA (antigen 9.2±5.5 μg/L and 9.7±4.7 μg/L, respectively; activity 1.3±0.5 IU/mL and 1.3±0.7 IU/mL, respectively) and PAI-1 (antigen 19.3±17.5 μg/L and 22.6±20.4 μg/L, respectively; activity 15.0±12.6 and 15.8±13.3 IU/mL, respectively) were observed. In conclusion, this study showed an association between mild hyperhomocysteinemia and VTE, but provided no evidence for an independent association between hyperhomocysteinemia and alterations in fibrinolytic proteins. Copyright (C) 2000 Elsevier Science Ltd.",
keywords = "Fibrinolysis, Homocysteine, Hyperhomocysteinemia, Vascular disease, Venous thromboembolism",
author = "Mojca Božič and Mojca Stegnar and Isabella Fermo and Anka Ritonja and Polona Peternel and Janez Stare and Armando D'Angelo",
year = "2000",
month = "11",
day = "15",
doi = "10.1016/S0049-3848(00)00324-8",
language = "English",
volume = "100",
pages = "271--278",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism

AU - Božič, Mojca

AU - Stegnar, Mojca

AU - Fermo, Isabella

AU - Ritonja, Anka

AU - Peternel, Polona

AU - Stare, Janez

AU - D'Angelo, Armando

PY - 2000/11/15

Y1 - 2000/11/15

N2 - Mild hyperhomocysteinemia is recognized as a risk factor for venous thromboembolism (VTE), though its role in the thrombogenic processes is not understood. Its possible association with impaired fibrinolysis was investigated in 157 patients (61 women, 96 men) below the age of 60 years (43±11, mean±SD) with a history of objectively confirmed VTE. Patients had significantly higher fasting total plasma homocysteine (tHcy) levels than 138 apparently healthy subjects (8.0, 6.6-9.9 μmol/L vs. 7.2, 5.9-8.6 μmol/L, P=0.001; median, range between first and third quartile). In 17 of 157 patients (12%) hyperhomocysteinemia (tHcy>11.4 μmol/L for women and tHcy>12.6 μmol/L for men) was established. The adjusted odds ratio as an estimate of relative risk for VTE was 2.3 (0.8-7.0; 95% confidence interval). When patients with hyperhomocysteinemia were compared to patients without hyperhomocysteinemia, no significant differences in t-PA (antigen 9.2±5.5 μg/L and 9.7±4.7 μg/L, respectively; activity 1.3±0.5 IU/mL and 1.3±0.7 IU/mL, respectively) and PAI-1 (antigen 19.3±17.5 μg/L and 22.6±20.4 μg/L, respectively; activity 15.0±12.6 and 15.8±13.3 IU/mL, respectively) were observed. In conclusion, this study showed an association between mild hyperhomocysteinemia and VTE, but provided no evidence for an independent association between hyperhomocysteinemia and alterations in fibrinolytic proteins. Copyright (C) 2000 Elsevier Science Ltd.

AB - Mild hyperhomocysteinemia is recognized as a risk factor for venous thromboembolism (VTE), though its role in the thrombogenic processes is not understood. Its possible association with impaired fibrinolysis was investigated in 157 patients (61 women, 96 men) below the age of 60 years (43±11, mean±SD) with a history of objectively confirmed VTE. Patients had significantly higher fasting total plasma homocysteine (tHcy) levels than 138 apparently healthy subjects (8.0, 6.6-9.9 μmol/L vs. 7.2, 5.9-8.6 μmol/L, P=0.001; median, range between first and third quartile). In 17 of 157 patients (12%) hyperhomocysteinemia (tHcy>11.4 μmol/L for women and tHcy>12.6 μmol/L for men) was established. The adjusted odds ratio as an estimate of relative risk for VTE was 2.3 (0.8-7.0; 95% confidence interval). When patients with hyperhomocysteinemia were compared to patients without hyperhomocysteinemia, no significant differences in t-PA (antigen 9.2±5.5 μg/L and 9.7±4.7 μg/L, respectively; activity 1.3±0.5 IU/mL and 1.3±0.7 IU/mL, respectively) and PAI-1 (antigen 19.3±17.5 μg/L and 22.6±20.4 μg/L, respectively; activity 15.0±12.6 and 15.8±13.3 IU/mL, respectively) were observed. In conclusion, this study showed an association between mild hyperhomocysteinemia and VTE, but provided no evidence for an independent association between hyperhomocysteinemia and alterations in fibrinolytic proteins. Copyright (C) 2000 Elsevier Science Ltd.

KW - Fibrinolysis

KW - Homocysteine

KW - Hyperhomocysteinemia

KW - Vascular disease

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0034668774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034668774&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(00)00324-8

DO - 10.1016/S0049-3848(00)00324-8

M3 - Article

C2 - 11113270

AN - SCOPUS:0034668774

VL - 100

SP - 271

EP - 278

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 4

ER -